<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cas16000" xml:lang="en" article-type="correction"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38073184</article-id><article-id pub-id-type="pmc">PMC10728001</article-id><article-id pub-id-type="doi">10.1111/cas.16000</article-id><article-id pub-id-type="publisher-id">CAS16000</article-id><article-categories><subj-group subj-group-type="overline"><subject>Correction</subject></subj-group><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction to Brigatinib in Japanese patients with <styled-content style="fixed-case" toggle="no">
<italic toggle="no">ALK</italic>
</styled-content>&#x02010;positive non&#x02010;small&#x02010;cell lung cancer: Final results of the phase 2&#x02009;<styled-content style="fixed-case" toggle="no">J&#x02010;ALTA</styled-content> trial</article-title><alt-title alt-title-type="left-running-head">ERRATUM</alt-title></title-group><pub-date pub-type="epub"><day>10</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>12</month><year>2023</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>114</volume><issue seq="270">12</issue><issue-id pub-id-type="doi">10.1111/cas.v114.12</issue-id><fpage>4776</fpage><lpage>4777</lpage><permissions><!--&#x000a9; 2023 Japanese Cancer Association--><copyright-statement content-type="article-copyright">&#x000a9; 2023 The Authors. <italic toggle="yes">Cancer Science</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japanese Cancer Association.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CAS-114-4776.pdf"/><related-article related-article-type="corrected-article" ext-link-type="doi" id="RA1" xlink:href="10.1111/cas.15888">10.1111/cas.15888</related-article><counts><fig-count count="2"/><table-count count="0"/><page-count count="2"/><word-count count="287"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.6 mode:remove_FC converted:18.12.2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="cas16000-body-0001"><p>Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, Ryohei Katayama, Makoto Nishio, Takashi Seto, Koichi Goto, Nobuyuki Yamamoto, Yuichiro Ohe, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Kazuhiko Nakagawa. Brigatinib in Japanese patients with ALK&#x02010;positive non&#x02010;small&#x02010;cell lung cancer: Final results of the phase 2 J&#x02010;ALTA trial. <italic toggle="yes">Cancer Sci</italic>. 2023;114:3698&#x02013;3707. doi:<ext-link xlink:href="https://doi.org/10.1111/cas.15888" ext-link-type="uri">10.1111/cas.15888</ext-link>.</p><p>The corrected Figure <xref rid="cas16000-fig-0001" ref-type="fig">2D</xref> and related statement in the legend is shown here:</p><fig position="float" fig-type="FIGURE" id="cas16000-fig-0001"><label>FIGURE 2</label><caption><p>
<bold>Efficacy in the main cohort (post&#x02010;alectinib&#x02009;&#x000b1;&#x02009;crizotinib; n&#x02009;=&#x02009;47).</bold> (A) DoR in patients with IRC&#x02010;assessed confirmed response. (B) PFS per IRC&#x02010;assessment. Twenty&#x02010;nine of 47 patients had events. (C) OS. At study end, 22 (47%) of 47 patients had died. (D) Intracranial PFS in all patients, regardless of intracranial disease status at baseline. In total, 15 of 47 patients had events of intracranial progression or death. For Kaplan&#x02013;Meier estimation of intracranial PFS, systemic PD followed by intracranial PD was considered an event, whereas patients who had systemic PD and withdrew from the study without intracranial PD were censored. Abbreviations: DoR, duration of response; IRC, independent review committee; OS, overall survival; PD, progressive disease; PFS, progression&#x02010;free survival.</p></caption><graphic xlink:href="CAS-114-4776-g001" position="anchor" id="jats-graphic-1"/></fig><fig position="float" fig-type="FIGURE" id="cas16000-fig-0002"><label>FIGURE 3B</label><graphic xlink:href="CAS-114-4776-g002" position="anchor" id="jats-graphic-3"/></fig><p>The corrected Figure <xref rid="cas16000-fig-0002" ref-type="fig">3B</xref> is shown here:</p><p>Errors in Figure S3 have been corrected in the Appendix S1 in the online Supporting Information section.</p><p>We apologize for this error.</p></body></article>
